Pulmonx buys Emphasys assets
Pulmonx is weighing the possibility of a new U.S. trial for the Emphasys EBV endobronchial valve for emphysema (formerly known as Zephyr) after acquiring the device and other assets of Emphasys Medical on May 13 for undisclosed terms. After nine years in the pipeline, Zephyr was found "not-approvable" by FDA following a negative advisory panel vote last December. Emphasys Medical subsequently put the technology on the auction block (1"The Gray Sheet" Feb. 23, 2009, p. 24). Pulmonx Executive VP and General Manager Niyazi Beyhan says his firm is considering a few options for Emphasys EBV, but will first focus on ramping up manufacturing to supply the valve to customers outside the U.S., where it has been sold since 2006. Palo Alto, Calif.-based Pulmonx touts the potential use of its 510(k)-pending Chartis collateral ventilation detection system to identify candidates best suited for endobronchial lung volume reduction procedures with Emphasys EBV
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
The Oncodetect test is tumor-informed, tracking up to 200 circulating tumor DNA (ctDNA) variants. It delivers simple “detected” or “not detected” results alongside quantitative data to guide adjuvant therapy decisions, monitor treatment response, and detects up to 200 ctDNA variants identifying signs of colorectal cancer recurrence up to two years earlier than imaging.
Diabetes company Insulet announced that former longtime J&J executive Ashley McEvoy will succeed Jim Hollingshead as president and CEO effective today. Analysts applauded the appointment, noting McEvoy’s strong background in medtech and diabetes.
Medtech Insight sat down with Jared Bunch, chair of AF Center of Excellence Task Force, at HRS 2025 to discuss the newly HRS released framework for Afib Center of Excellence and get his perspective on the role industry could play to help clinicians improve patient outcomes.